Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novo Hemophilia Drug's Postmarket Monitoring Plan Not Robust Enough – US Panel

Apr 05 2017

• By Sue Sutter

Related Content

Novo Nordisk’s Hemophilia B Drug Faces Safety Scrutiny By US FDA Panel

Mar 31 2017

Related Companies

Novo Nordisk A/S

Biogen, Inc.

CSL Limited

Additional Topics

United States Advisory Committees Drug Review Regulation BioPharmaceutical Blood & Coagulation Disorders

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.